Commonwealth Equity Services
DNA icon

Commonwealth Equity Services’s Ginkgo Bioworks DNA Stock Holding History

Commonwealth Equity Services’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-7,637
Closed -$102K – 4095
2024
Q2 		$102K Sell
7,637
-1,905
-20% -$56.8K ﹤0.01% 3810
2024
Q1 		$443K Buy
9,542
+94
+1% +$4.87K ﹤0.01% 2923
2023
Q4 		$639K Buy
9,448
+221
+2% +$13.5K ﹤0.01% 2514
2023
Q3 		$668K Buy
9,227
+3,174
+52% +$254K ﹤0.01% 2346
2023
Q2 		$450K Buy
6,053
+1,339
+28% +$79.3K ﹤0.01% 2714
2023
Q1 		$250K Buy
4,714
+575
+14% +$36.4K ﹤0.01% 3119
2022
Q4 		$279K Sell
4,139
-285
-6% -$26.2K ﹤0.01% 2927
2022
Q3 		$552K Buy
4,424
+932
+27% +$111K ﹤0.01% 2323
2022
Q2 		$332K Buy
3,492
+1,100
+46% +$134K ﹤0.01% 2745
2022
Q1 		$385K Buy
2,392
+645
+37% +$126K ﹤0.01% 2747
2021
Q4 		$580K Sell
1,747
-176
-9% -$83.6K ﹤0.01% 2403
2021
Q3 		$891K Buy
+1,923
New +$936K ﹤0.01% 2011

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Commonwealth Equity Services's DNA Position: Q3 2024 in Review

Commonwealth Equity Services sold out of Ginkgo Bioworks (DNA) in Q3 2024, closing a stake of 7,637 shares — an estimated $102K sold.

Commonwealth Equity Services first reported a position in DNA in Q3 2021 and held it in 12 quarters. The position peaked at $891K in Q3 2021. 159 funds tracked by Wall St. Rank hold DNA as of Q3 2024.

  • Commonwealth Equity Services reported no remaining Ginkgo Bioworks position as of Q3 2024 after selling out during the quarter.
  • Commonwealth Equity Services sold 7,637 Ginkgo Bioworks shares in Q3 2024, an estimated $102K.
  • Commonwealth Equity Services first reported a position in Ginkgo Bioworks in Q3 2021 and held it in 12 quarters.
  • Commonwealth Equity Services's Ginkgo Bioworks position peaked at $891K in Q3 2021.
  • 159 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2024.

Based on Commonwealth Equity Services's 13F filing for Q3 2024, filed 18 Oct 2024.